Last reviewed 2026-04-20 · How we verify

INCB028060

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Diarrhoea
• Oedema peripheral
• Fatigue
• Constipation
• Vomiting
• Anaemia
• Arthralgia
• Blood creatine phosphokinase increased
• Alanine aminotransferase increased
• Decreased appetite
• Pruritus

Key clinical trials

• Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (PHASE2)
• Managed Access Programs for INC280, Capmatinib
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (PHASE1, PHASE2)
• Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone (PHASE2)
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
• Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (PHASE1)
• Molecular Profiling of Advanced Soft-tissue Sarcomas (PHASE3)
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• INCB028060 CI brief — competitive landscape report
• INCB028060 updates RSS · CI watch RSS
• Incyte Corporation portfolio CI